<DOC>
	<DOCNO>NCT00003414</DOCNO>
	<brief_summary>RATIONALE : Cyclosporine may induce graft-versus-host disease make body build immune response kill cancer cell . Interleukin-2 interferon gamma may enhance effectiveness graft-versus-host disease kill cancer cell . PURPOSE : Randomized phase III trial determine effectiveness graft-versus-host disease treat patient recurrent refractory lymphoma Hodgkin 's disease .</brief_summary>
	<brief_title>Graft-Versus-Host Disease Treating Patients With Recurrent Refractory Lymphoma Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether autologous graft versus host disease significantly alter relapse rate lymphoma Hodgkin 's disease autologous bone marrow transplantation . OUTLINE : This randomize study . Stem cell harvest cryopreserved . All patient receive busulfan/cyclophosphamide cyclosporine/total body irradiation preparative regimen . Arm I : Patients randomize graft versus host disease ( GVHD ) induction arm receive oral cyclosporine twice day begin day 0 continue least 28 day , follow peripheral blood stem cell ( PBSC ) infusion . At time white blood cell count begin recover , subcutaneous interferon gamma administer 10 dos , follow 2 day later subcutaneous interleukin-2 ( IL-2 ) 18 dos . Arm II : Patients receive autologous GVHD therapy PBSC transplant . Both arm receive radiation site lymphoma recover stem cell transplantation . Patients follow 6 month , 1 year , 2 year posttransplant . PROJECTED ACCRUAL : Approximately 50 patient ( 25 per arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients receive autologous syngeneic peripheral blood stem cell transplant chemotherapy refractory recurrent lymphoma Hodgkin 's disease , include : Progressive disease within 6 week complete initial induction therapy OR Failure achieve least overall partial response ( least 50 % reduction tumor size ) conventional salvage therapy follow relapse PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : No capillary leak syndrome Hepatic : Bilirubin great 5 mg/dL Renal : Creatinine le 4 mg/dL No renal failure require dialysis Cardiovascular : No hypotension No severe venooclusive disease Pulmonary : No pulmonary infiltrates OR No requirement great 2 L oxygen Other : No weight gain great 5 % baseline weight No concurrent sepsis No temperature 39 degree C high two day No clinically evident ascites PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior chemotherapy allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>